<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d153" origId="Aminohippurate"><sentence id="DrugDDI.d153.s0" origId="s0" text="Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone."><entity id="DrugDDI.d153.s0.e0" origId="s0.p8" charOffset="103-115" type="drug" text="sulfonamides"/><entity id="DrugDDI.d153.s0.e1" origId="s0.p9" charOffset="117-125" type="drug" text="procaine"/><pair id="DrugDDI.d153.s0.p0" e1="DrugDDI.d153.s0.e0" e2="DrugDDI.d153.s0.e1" interaction="?"/></sentence><sentence id="DrugDDI.d153.s1" origId="s1" text="These compounds interfere with chemical color development essential to the analytical procedures."/><sentence id="DrugDDI.d153.s2" origId="s2" text="Probenecid depresses tubular secretion of certain weak acids such as PAH."><entity id="DrugDDI.d153.s2.e0" origId="s2.p16" charOffset="0-10" type="drug" text="Probenecid"/></sentence><sentence id="DrugDDI.d153.s3" origId="s3" text="Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values."><entity id="DrugDDI.d153.s3.e0" origId="s3.p24" charOffset="30-40" type="drug" text="probenecid"/></sentence></document>